Executive at Trevi (NASDAQ: TRVI) granted 160,000 stock options

Rhea-AI Filing Summary

Simon Farrell reported acquisition or exercise transactions in this Form 4 filing.

Trevi Therapeutics Chief Commercial Officer Simon Farrell received a grant of stock options covering 160,000 shares of common stock. The award was made on February 19, 2026 as an equity incentive.

The 160,000 underlying shares are scheduled to vest in equal monthly installments through February 19, 2030, conditioned on Farrell’s continued service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Simon Farrell

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	160,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 160,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Farrell

(Last) (First) (Middle)

C/O TREVI THERAPEUTICS, INC.

195 CHURCH STREET, 16TH FLOOR

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Trevi Therapeutics, Inc. [ TRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.56	02/19/2026		A		160,000		(1)	02/18/2036	Common Stock	160,000	$0	160,000	D

Explanation of Responses:

1. This option was granted on February 19, 2026. The 160,000 shares of common stock underlying the option are scheduled to vest in equal monthly installments through February 19, 2030, subject to the reporting person's continued service with the issuer.

	/s/ Christopher Galletta, attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Trevi Therapeutics (TRVI) disclose about Simon Farrell in this Form 4?

Trevi Therapeutics disclosed that Chief Commercial Officer Simon Farrell received a stock option grant for 160,000 shares of common stock on February 19, 2026. This Form 4 records the equity award as part of his compensation package.

How many Trevi Therapeutics (TRVI) stock options were granted to Simon Farrell?

Simon Farrell was granted options over 160,000 shares of Trevi Therapeutics common stock. According to the filing, this entire amount remains outstanding after the transaction and represents a new equity award rather than an open-market purchase or sale.

What is the vesting schedule for Simon Farrell’s Trevi Therapeutics (TRVI) stock options?

The 160,000-share stock option grant to Simon Farrell is scheduled to vest in equal monthly installments through February 19, 2030. Vesting depends on his continued service with Trevi Therapeutics over that multi-year period.

Does the Trevi Therapeutics (TRVI) Form 4 show a buy or sell by Simon Farrell?

The Form 4 does not show a market buy or sell. Instead, it reports an option grant, classified as a “grant, award, or other acquisition” of derivative securities, giving Farrell rights to acquire 160,000 shares over time if conditions are met.

What role does Simon Farrell hold at Trevi Therapeutics (TRVI) in this Form 4?

Simon Farrell is identified as Chief Commercial Officer of Trevi Therapeutics. The reported stock option grant represents part of his officer compensation, aligning his potential future ownership of up to 160,000 shares with the company’s performance and his continued service.

Are Simon Farrell’s Trevi Therapeutics (TRVI) options held directly or indirectly?

The filing classifies Simon Farrell’s ownership of the reported options as direct. There is no indication in the footnotes that another entity, such as a trust or family partnership, holds voting or investment power over this 160,000-share stock option award.